Albiglutide: a new anti-diabetic drug of human glucagon-like peptide analogue

Albiglutide, a long-acting human glucagon-like peptide analogue, was approved by the European Medicines Agency at 26th March and by the U.S. Food and Drug Administration at 15th April, 2014. A subcutaneous injection of albiglutide, once a week, can improve glycemic control along with diet and exercise in adults with type 2 diabetes. The clinical studies of albiglutide for the treatment of type 2 diabetes have been summarized. Its safety and effectiveness have been also evaluated. Compared with placebo, albiglutide improves glycemic control with significant reductions from baseline in glycosylated hemoglobin, in fasting plasma glucose and postprandial glucose excursions, and in weight loss. Due to its better long-term stability and safety, albiglutide is a new choice for the treatment of type 2 diabetes.